Essential thrombocythemia: Biology, clinical features, thrombotic risk, therapeutic options and outcome-Reference-Cited by-同舟云学术

Essential thrombocythemia: Biology, clinical features, thrombotic risk, therapeutic options and outcome

Published:2019-09-02 Issue:1 Volume:3 Page:053-059
ISSN:2640-2823
Container-title:Journal of Hematology and Clinical Research
language:
Short-container-title:J Hematol Clin Res

Author:

Accurso V^ORCID,Santoro M,Contrino AD,Casimiro P,Raso S

Publisher

Heighten Science Publications Corporation

Subject

General Engineering

Link

https://www.hematologyresjournal.com/articles/jhcr-aid1012.pdf

Reference73 articles.

1. 1. Daniel AA, Attilio Orazi, Robert Hasserjian, Thiele J, Borowitz MJ, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. BLOOD. 2016; 127: 20. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27069254

2. 2. Ma X, Vanasse G, Cartmel B, Wang Y, Selinger HA. Prevalence of polycythemia vera and essential thrombocythemia. Am J Hematol. 2008; 83: 359-362. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18181200

3. 3. Johansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006; 32: 171-173. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16673273

4. 4. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990; 8: 556-562. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/2307991

5. 5. Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, et al. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990; 66: 549-556. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/2364366